Back

METAHEL CURE PRIVATE LIMITED

PLOT NO. 94M2, SECTOR-6A, IIE, SIDCUL,

Product Categories

Formulations
ABACAVIR (100 MG) + LAMIVUDINE (300 MG),VILDAGLIPTIN (50 MG) + METFORMIN (1000 MG)

Company Profile

WE'RE PHARMACEUTICAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANISATION (CDMO) COMPANY DEDICATED TO DEVELOPING AND PRODUCING INNOVATIVE MEDICINES (TABELTS, CAPSULES, ORAL LIQUIDS) TO IMPROVE GLOBAL HEALTH. FOUNDED ON PRINCIPLES OF INTEGRITY, EXCELLENCE, AND COMPASSION, WE STRIVE TO MAKE A POSITIVE IMPACT ON PEOPLE'S LIVES BY PROVIDING HIGH-QUALITY, AFFORDABLE HEALTHCARE SOLUTIONS. OUR COMPANY IS COMMITTED TO PUSHING THE BOUNDARIES OF MEDICAL SCIENCE TO ADDRESS UNMET MEDICAL NEEDS AND IMPROVE PATIENT OUTCOMES. WE INVEST IN CUTTING-EDGE RESEARCH AND DEVELOPMENT EFFORTS TO DISCOVER AND DEVELOP NOVEL THERAPIES THAT HAVE THE POTENTIAL TO TRANSFORM THE TREATMENT LANDSCAPE. AT METAHEL CURE, WE PRIORITISE PATIENT-CENTRICITY IN EVERYTHING WE DO. WE UNDERSTAND THE IMPORTANCE OF ACCESS TO HEALTHCARE, AND WE WORK TIRELESSLY TO ENSURE THAT OUR MEDICINES REACH THOSE WHO NEED THEM MOST, REGARDLESS OF GEOGRAPHICAL LOCATION OR SOCIOECONOMIC STATUS.